{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Physician%27s+choice", "query": { "intervention": "Physician's choice" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 179, "total_pages": 18, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Physician%27s+choice&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-24T21:52:07.294Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04711824", "title": "Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Brain Metastases, Adult" ], "interventions": [ { "name": "Olaparib", "type": "DRUG" }, { "name": "Stereotactic Radiosurgery", "type": "RADIATION" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Physicians Choice systemic chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Colette Shen", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2022-03-09", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2026-07-10", "last_synced_at": "2026-09-24T21:52:07.294Z", "location_count": 7, "location_summary": "Birmingham, Alabama • Hollywood, Florida • Indianapolis, Indiana + 4 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "New York", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04711824" }, { "nct_id": "NCT04570423", "title": "A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumors", "Lymphoma" ], "interventions": [ { "name": "Eflapegrastim", "type": "DRUG" }, { "name": "Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Spectrum Pharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Month", "maximum_age": "17 Years", "sex": "ALL", "summary": "1 Month to 17 Years" }, "enrollment_count": 40, "start_date": "2021-05-20", "completion_date": "2027-10", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-09-24T21:52:07.294Z", "location_count": 5, "location_summary": "Valhalla, New York • Charlotte, North Carolina • Cleveland, Ohio + 1 more", "locations": [ { "city": "Valhalla", "state": "New York" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04570423" }, { "nct_id": "NCT06624644", "title": "A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Melanoma (Skin Cancer)", "Melanoma Stage IIIB-IV", "Cutaneous Melanoma", "Unresectable Melanoma" ], "interventions": [ { "name": "LNS8801", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Chemotherapy (dacarbazine or temozolomide)", "type": "DRUG" }, { "name": "Immunotherapy (Pembrolizumab)", "type": "BIOLOGICAL" }, { "name": "Immunotherapy (nivolumab and relatlimab)", "type": "BIOLOGICAL" }, { "name": "Immunotherapy (ipilimumab and nivolumab)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Linnaeus Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 135, "start_date": "2025-08-06", "completion_date": "2031-02", "has_results": false, "last_update_posted_date": "2026-04-22", "last_synced_at": "2026-09-24T21:52:07.294Z", "location_count": 9, "location_summary": "Newport Beach, California • San Francisco, California • Stanford, California + 6 more", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06624644" }, { "nct_id": "NCT07060807", "title": "A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "Patritumab deruxtecan", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Liposomal doxorubicin", "type": "DRUG" }, { "name": "Trastuzumab deruxtecan", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1000, "start_date": "2025-07-21", "completion_date": "2033-07-14", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-09-24T21:52:07.294Z", "location_count": 34, "location_summary": "Daphne, Alabama • Tucson, Arizona • Los Angeles, California + 27 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Grand Junction", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT07060807" }, { "nct_id": "NCT03517449", "title": "Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Endometrial Neoplasms" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 827, "start_date": "2018-06-11", "completion_date": "2025-02-26", "has_results": true, "last_update_posted_date": "2026-03-19", "last_synced_at": "2026-09-24T21:52:07.294Z", "location_count": 25, "location_summary": "Phoenix, Arizona • San Francisco, California • Santa Monica, California + 22 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03517449" }, { "nct_id": "NCT06463665", "title": "Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Non-squamous Non-small-cell Lung Cancer", "Advanced Squamous Non-Small Cell Lung Carcinoma", "Metastatic Non-squamous Non Small Cell Lung Cancer", "Metastatic Squamous Non-Small Cell Lung Carcinoma", "Non-small Cell Lung Cancer", "Non-small Cell Lung Cancer Stage III", "Non-small Cell Lung Cancer Stage IV", "Non-small Cell Lung Cancer Recurrent" ], "interventions": [ { "name": "Olvimulogene nanivacirepvec", "type": "BIOLOGICAL" }, { "name": "Platinum chemotherapy: carboplatin or cisplatin", "type": "DRUG" }, { "name": "Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC", "type": "DRUG" }, { "name": "Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Genelux Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 142, "start_date": "2024-09-26", "completion_date": "2029-07", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-09-24T21:52:07.294Z", "location_count": 15, "location_summary": "Bullhead City, Arizona • Clermont, Florida • Coral Springs, Florida + 11 more", "locations": [ { "city": "Bullhead City", "state": "Arizona" }, { "city": "Clermont", "state": "Florida" }, { "city": "Coral Springs", "state": "Florida" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Hialeah", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06463665" }, { "nct_id": "NCT02555735", "title": "Exceptional Responders With Solid Tumor Cancer to Chemotherapy", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Solid Tumor Neoplasms" ], "interventions": [ { "name": "Standard of Care Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Adera Labs, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 250, "start_date": "2015-10", "completion_date": "2027-08", "has_results": false, "last_update_posted_date": "2023-02-01", "last_synced_at": "2026-09-24T21:52:07.294Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02555735" }, { "nct_id": "NCT01243892", "title": "A Study to Evaluate Growth in Participants Treated With Somatropin (Nutropin) Using NuSpin Device", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Growth Hormone Deficiency" ], "interventions": [ { "name": "NuSpin", "type": "DEVICE" }, { "name": "Somatropin", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "14 Years", "sex": "ALL", "summary": "2 Years to 14 Years" }, "enrollment_count": 18, "start_date": "2010-11", "completion_date": "2011-08", "has_results": true, "last_update_posted_date": "2016-12-01", "last_synced_at": "2026-09-24T21:52:07.294Z", "location_count": 14, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Sacramento, California + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Greenwood Village", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01243892" }, { "nct_id": "NCT03083808", "title": "Phase II Trial of Continuation Therapy in Advanced NSCLC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small-Cell Lung Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Greg Durm, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2017-03-20", "completion_date": "2022-03-03", "has_results": true, "last_update_posted_date": "2023-08-24", "last_synced_at": "2026-09-24T21:52:07.294Z", "location_count": 5, "location_summary": "Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 2 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT03083808" }, { "nct_id": "NCT01419197", "title": "A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Trastuzumab emtansine", "type": "DRUG" }, { "name": "Treatment of physician's choice", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 602, "start_date": "2011-09", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2016-10-12", "last_synced_at": "2026-09-24T21:52:07.294Z", "location_count": 59, "location_summary": "Tucson, Arizona • Hot Springs, Arkansas • Hayward, California + 52 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Hayward", "state": "California" }, { "city": "Highland", "state": "California" }, { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01419197" } ] }